Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754063 | 0.81 | ALDH1A1 (0.40) | LMNAALDH1A1TRPA1PPARAPPARG | |
| SCHEMBL5317773 | 0.78 | ASAH1 (0.40) | ALDH1A1 | |
| SCHEMBL13754074 | 0.75 | ALDH1A1 (0.43) | LMNAALDH1A1CYP3A4POLB | |
| SCHEMBL10824109 | 0.74 | LMNA (0.37) | LMNAALDH1A1PPARAPPARGCYP3A4 | |
| SCHEMBL13754069 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CYP3A4 | |
| SCHEMBL5315005 | 0.74 | ATM (0.31) | CYP3A4 | |
| SCHEMBL13754072 | 0.72 | HDAC7 (0.44) | ALDH1A1CYP3A4POLB | |
| SCHEMBL20496665 | 0.70 | MEN1 (0.37) | LMNAALDH1A1CYP3A4NOS3NOS2 | |
| SCHEMBL17589051 | 0.70 | MEN1 (0.37) | LMNAALDH1A1CYP3A4NOS3NOS2 | |
| SCHEMBL4057730 | 0.68 | ALDH1A1 (0.38) | LMNAALDH1A1PPARAPPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314246-B2 | Catalytic reactions involving alkenes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20090216025-A1 | Catalytic reactions involving alkenes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2007027752-A1 | CATALYTIC REACTIONS INVOLVING ALKENES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216025-A1 | Catalytic reactions involving alkenes | ADH5, ADH1C, ADH1A | LMNA 2832/4885ALDH1A1 15/4885TRPA1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.